Latest Close
$28.14
News
AGIO
Agios Pharmaceuticals, Inc. News
This news view pulls recent coverage and headlines tied to AGIO.
1y Change
-$1.66 (-5.57%)
Market Cap
$1.67B
Sector
Healthcare
Industry
Biotechnology
Recommendation
buy
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Business Wire • May 22, 2026
Read articleAgios Gets EU Approval for Pyrukynd in Thalassemia
MT Newswires • May 22, 2026
Read articleAgios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
GlobeNewswire • May 22, 2026
Read articleAgios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
MarketBeat • May 19, 2026
Read articleAssessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility
Simply Wall St. • May 15, 2026
Read articleHow Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story
Simply Wall St. • May 15, 2026
Read article